Elsevier

Medicina Clínica

Volume 148, Issue 6, 22 March 2017, Pages 271-276
Medicina Clínica

Diagnóstico y tratamiento
Diagnóstico y tratamiento de la gotaGout: Diagnosis and treatment

https://doi.org/10.1016/j.medcli.2016.10.019Get rights and content

Section snippets

Identificación de cristales (patrón oro)

La identificación de cristales de UMS en líquido sinovial o en material aspirado de tofos sigue constituyendo el patrón oro para el diagnóstico de gota, como afirman las recomendaciones y guías de práctica clínica1, 2, 3; esto también deriva de entender la gota como una enfermedad por depósito de cristales de UMS.

Su identificación resulta sencilla y fiable tras un corto entrenamiento. Se precisa un microscopio óptico equipado con 400-600 aumentos, que permiten una adecuada visualización de los

Objetivos

El depósito de cristales de UMS en pacientes con gota es reversible. Por tanto, la estrategia de tratamiento tiene como objetivo (irrenunciable) la eliminación de los depósitos de UMS (tabla 1). Sin cristales, no existe inflamación (ni ataques agudos, ni inflamación subclínica mantenida), por lo que la gota se puede considerar curada. El único método conocido para disolver los depósitos es reducir la uricemia por debajo de su punto de saturación de manera mantenida. En pacientes gotosos la

Conclusiones

  • El diagnóstico de la gota se debe realizar en base a la identificación de cristales de UMS en una muestra de líquido sinovial o en un aspirado de tofo.

  • El objetivo del tratamiento de la gota es la disolución de los depósitos de cristales. Para conseguirlo debemos reducir la uricemia < 6 mg/dl. En pacientes seleccionados se deben considerar objetivos de tratamiento más estrictos (< 5 mg/dl), ya que a menor uricemia, mayor rapidez de disolución de los cristales.

  • Las opciones iniciales de tratamiento

Conflicto de intereses

FS ha recibido honorarios por material educativo y por ponencias de Menarini y ha participado en advisory board para AstraZeneca. MA ha recibido honorarios por ponencias de Menarini y ha participado en advisory board para AstraZeneca. NQ declara no tener ningún conflicto de intereses.

Bibliografía (30)

  • H.J. Janssens et al.

    Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial

    Lancet

    (2008)
  • H.K. Choi et al.

    Alcohol intake and risk of incident gout in men: A prospective study

    Lancet

    (2004)
  • F. Sivera et al.

    Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

    Ann Rheum Dis

    (2014)
  • Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based...
  • D. Khanna et al.

    American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

    Arthritis Care Res (Hoboken)

    (2012)
  • E. Pascual et al.

    Synovial fluid analysis for diagnosis of intercritical gout

    Ann Intern Med

    (1999)
  • E. De Miguel et al.

    Diagnosis of gout in patients with asymptomatic hyperuricaemia: A pilot ultrasound study

    Ann Rheum Dis

    (2012)
  • N. Dalbeth et al.

    Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: A dual energy CT study

    Ann Rheum Dis

    (2015)
  • M. Andrés et al.

    Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: An exploratory study

    Arthritis Rheumatol

    (2016)
  • A. Abhishek et al.

    In vivo detection of monosodium urate crystal deposits by Raman spectroscopy--A pilot study

    Rheumatology

    (2016)
  • F. Perez-Ruiz et al.

    An audit of the variability of diagnosis and management of gout in the rheumatology setting: The gout evaluation and management study

    J Clin Rheumatol

    (2011)
  • A. Malik et al.

    Clinical diagnostic criteria for gout: Comparison with the gold standard of synovial fluid crystal analysis

    J Clin Rheumatol

    (2009)
  • R.B. Landewe et al.

    EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee

    Ann Rheum Dis

    (2010)
  • T. Neogi et al.

    Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

    Ann Rheum Dis

    (2015)
  • O.O. Seminog et al.

    Gout as a risk factor for myocardial infarction and stroke in England: Evidence from record linkage studies

    Rheumatology (Oxford)

    (2013)
  • Cited by (14)

    • Coffea arabica extracts and their chemical constituents in a murine model of gouty arthritis: How they modulate pain and inflammation

      2022, Journal of Ethnopharmacology
      Citation Excerpt :

      Gout is characterised by painful inflammatory arthritis resulting from the deposition of MSU crystals in joints (Sivera et al., 2016).

    • Lychnophora pinaster's effects on inflammation and pain in acute gout

      2021, Journal of Ethnopharmacology
      Citation Excerpt :

      Hyperuricemia can cause the precipitation and deposition of urate crystals in joint spaces, which leads to a disease known as “gout” (Mediavilla and Miguel, 2011; Sivera et al., 2016).

    • Emergent nanotherapies in microcrystal-induced arthritis

      2018, International Immunopharmacology
      Citation Excerpt :

      Principles of long term gout management include the appropriate use of urate-lowering therapy (ULT) to keep serum urate at or below 6 mg/dL and to treat acute gout flares with short-term anti-inflammatory drugs such as corticosteroids, COL, or NSAIDs. ULT options include xanthine oxidase inhibitors, such as allopurinol (ALLO) and febuxostat, with a much lower use of uricosurics, including probenecid and benzbromarone, which inhibit tubular resorption of UA by the URAT-1 transporter and produces a significant reduction in UA levels, at least as important as that achieved with ALLO [19, 20]. With emerging evidence of the possible roles of hyperuricemia in cardiometabolic comorbidities, as well as more convincing evidence regarding poor outcomes in patients with uncontrolled gout, several agents are currently under development.

    View all citing articles on Scopus
    View full text